PHILADELPHIA, April 1, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders and Max Neeman International is one of the leading and largest clinical research organizations ("CROs") in India. They jointly announced today a collaborative clinical research effort for one of Hemispherx' flagship products, Alferon N Injection® (interferon Alfa-n3).
